Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin Coagulation Test Effects in Healthy Volunteers
NCT02357524Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Melinta Therapeutics. Primary endpoint: Time to resolution of elevations in coagulation test results at 120 hours. Started Jan 2015; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02357524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357524.